Clinical Trials Logo
  1. Home
  2. High Risk Neuroblastoma
  3. NCT04501757

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma Clinical Trial

Official title:
Expanded Access Use of Naxitamab/GM-CSF Immunotherapy for Consolidation of Complete Remission or Relapsed/Refractory High-Risk Neuroblastoma

Clinical Trial Summary

This is an Expanded Access Program (EAP) that will give the participants access to the drug naxitamab before it is approved by the FDA. Naxitamab will be combined with granulocyte-macrophage colony stimulating factor (GM-CSF). Participants in this study will have high-risk neuroblastoma that either went away completely after treatment (complete remission) or has come back (relapsed/refractory). Researchers think the combination of naxitamab and GM-CSF will be effective because naxitamab and GM-CSF strengthen the immune system's response to cancer cells in different ways. Naxitamab is an antibody, like the proteins made by the immune system to protect the body from harm. Naxitamab helps the cells of the immune system to find and attack cancer cells. GM-CSF is a protein that strengthens the immune system by increasing the number of immune cells called granulocytes. Granulocytes are white blood cells that fight off cancer cells. The combination of naxitamab and GM-CSF is a type of immunotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04501757
Study type Expanded Access
Source Memorial Sloan Kettering Cancer Center
Contact
Status No longer available
Phase
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06057948 - A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma Phase 2
Not yet recruiting NCT06335745 - PediCARE Health Equity Intervention in High-Risk Neuroblastoma N/A
Recruiting NCT05489887 - Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Phase 2
Recruiting NCT04221035 - High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Phase 3
Recruiting NCT05650749 - GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma Phase 1
Completed NCT05373901 - Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma Phase 1
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Recruiting NCT05272371 - Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease Phase 1